Stock in Focus
Cell Therapeutics, Inc. (Public, NASDAQ:CTIC)

Cell Therapeutics will spend $10 million to buy rights to an anti-cancer drug owned by Chroma Therapeutics, will CTIC follow through?. Cell Therapeutics also said that in trials, Chroma's drug had demonstrated significant anti-tumor responses in blood related cancers and solid tumors.

Kraig Biocraft Laboratories Inc (Public, PINK:KBLB)

Huge volume and decent gains today, will tomorrow follow siute. WATCH